



Qualitative Detection of Drugs of Abuse in Human Saliva: Amphetamine, Opiates, Cocaine, Methamphetamine, MDMA, Benzodiazepines, and Marijuana (THC)

INTENDED USE

ToxWipe™ is a rapid lateral flow immunoassay for the qualitative detection of drugs of abuse in human saliva.

Up to 7 commonly abused drugs and drug metabolites can be detected including Amphetamine, Opiates, Cocaine, Methamphetamine, MDMA, Benzodiazepines, and Marijuana (THC).

ToxWipe™ Cut-off Concentrations:

Test	Cut-off (ng/mL, ppb)
Amphetamine (AM)	50
Methamphetamine / MDMA (ME)	50/100
Cocaine (CO)	20
Opiates (OP)	40
Marijuana (TH)	25
Benzodiazepines (BZ)	10

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) and gas chromatography/ tandem mass spectrometry (GC/MS/MS) are the preferred confirmatory methods. Professional judgment should be applied to any drug of abuse test result particularly when preliminary positive results are indicated.

ToxWipe™ is for professional use only and not for medical diagnostic purposes.

SUMMARY

ToxWipe™ is a preliminary onsite screening test for up to 7 commonly abused drugs and drug metabolites, including Amphetamine, Opiates, Cocaine, Methamphetamine, MDMA, Benzodiazepines, and Marijuana (THC). The test can detect drug in human saliva.

Drugs can be rapidly metabolized in the blood after consumption via different routes¹. Detection of drugs or drug metabolites in body fluids, such as blood, urine, and saliva can reveal recent drug use².

Saliva testing is becoming increasingly popular for drug testing due to its non-invasive and convenient sample collection³. In recent years, different studies have indicated a close correlation between the concentration of drugs and their metabolites in blood samples and in saliva samples⁴⁻⁵. Saliva collection is performed by "face to face" collection and therefore prevents sample adulteration and eliminates privacy concerns. Saliva collection can be easily and repeatedly performed under a variety of circumstances.

ToxWipe™ is designed for user-friendly onsite rapid drug testing using saliva specimens. The innovative design of **ToxWipe™** allows users to test for drugs of abuse with minimal sample collection time.

TEST PRINCIPLE

The **ToxWipe™** is an immunoassay based on the principle of competitive binding. Drugs which may be present in the specimen compete against their respective drug conjugate for binding sites on their specific antibody.

During testing, the specimen migrates by capillary action.

A drug, if present in the specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody and a colored line will not form in the test line region.

A drug-positive specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative specimen will generate a line in the test line region because there is no drug competition.

To serve as a procedural control, a colored line will appear at the control line region if the test has been performed properly.

PRECAUTIONS

- **ToxWipe™** is for professional use only and not for medical diagnostic purposes.
- **ToxWipe™** is intended for testing human saliva specimens.
- It is recommended that donor avoid eating, drinking or smoking within 10 minutes before testing.
- When placing the collection pad in mouth for saliva collection, the donor must not chew any part of the tip. Do not place the collection pad in mouth for more than 3 minutes.
- Do not use after the expiration date indicated on the package. Do not use the test if the foil pouch is damaged. Do not reuse tests. Read the entire procedure carefully prior to testing.
- Handle all specimens as if they contain infectious agents. Follow established precautions against microbiological hazards throughout the procedure and follow standard procedures for the proper disposal of specimens.
- Humidity and temperature can adversely affect results.
- This test is for single use. Used testing materials should be discarded in accordance with local regulations.

STORAGE AND STABILITY

Store the original package at 2-30°C. Check the expiration date on the foil pouch. Do not use if the package is damaged or expired. The test device should remain in its original sealed pouch until use. Do not freeze.

MATERIALS

Each package contains:

- **ToxWipe™** device
- Device cap with a sealed reagent chamber
- Desiccant pack

Materials required but not provided:

- Timer
- Gloves

DIRECTIONS FOR USE

Allow the ToxWipe™ device to come to room temperature [15-30°C (59-86°F)] prior to testing. For saliva testing, instruct the donor not to place anything in the mouth including food, drink, gum, or tobacco products for at least 10 minutes prior to collection.

1. Remove the test device from the sealed foil pouch.

2. Collect and add sample as follows:



Insert collection pad into mouth. Actively swab around the gums and tongue before placing the collection pad under tongue to aid specimen collection. When sufficient saliva has been collected to run the test at least one of the blue lines at the bottom of the display windows will disappear/wick up. The saliva specimen should only touch the absorbent area. Do not swipe the test device at any point above the visible outer collection pad.

3. Peel the cover off of the sealed cavity of the reagent cap and insert the collection pad of the test device all the way in. Alternatively, use the corner of the device tip to puncture the middle of the cover of the sealed cavity (see Step 3 illustration below) and push the collection pad of the test device all the way in. Place the test device on a flat surface and set a timer.

4. Read the test results at 3 - 5 minutes. See illustration below.

If all lines are visible at 3 minutes then the test can be interpreted as negative and discarded. If all lines are not visible at 3 minutes then the test should be re-read at 5 minutes.

Do not interpret results after 5 minutes.



INTERPRETATION OF TEST VALIDITY AND RESULTS

(Please refer to the previous illustration)

NEGATIVE:* All test lines appear. A colored line in the control region (C), and a colored line in the test region for specific drug indicate a negative result. This negative result indicates that the drug concentration is below the cut-off level for that specific drug.

***NOTE:** The shade of color in the test region will vary, but it should be considered negative whenever there is even a faint colored line.

POSITIVE: A colored line in the control region (C) but no line in the test region regions for a specific drug indicates a positive result. This positive result indicates that the drug concentration is above the cut-off level for that specific drug.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test. If the problem persists, discontinue using the lot immediately and contact your supplier.

TEST LIMITATIONS

- ToxWipe™** is a qualitative test only, and cannot determine the frequency of drug use or concentration of drugs or drug metabolites in the sample. The test is intended to distinguish a preliminary positive result from a negative result.
- There is a possibility that technical or procedural errors as well as interfering substances may cause false results.
- The test does not distinguish between drugs of abuse and certain medications.
- A positive result indicates the presence of a drug only, and does not indicate or measure intoxication.
- A negative result does not at any time rule out the presence of drugs in tested sample, as they may be present below the minimum detection level.
- Under certain physiological or pathological conditions, such as waking from sleep in the early morning or dry mouth syndrome, saliva collection time may be prolonged.

QUALITY CONTROL

The control line of the test device is a built-in quality control feature. The quality control test serves to confirm the testing procedure, liquid flow and general antibody-antigen binding are properly functional. This control line should appear regardless of the presence of drug or metabolite.

PERFORMANCE CHARACTERISTICS

Analytical Sensitivity

Analytical precision was evaluated by testing spiked saliva controls with 3 lots of product. Each lot was tested at concentration levels of negative, -50%, +50% and +100% of the cut-off level.

Conc. Relative to Cut-off Level	AMP		OPI		COC		MET		BZO		THC	
	-	+	-	+	-	+	-	+	-	+	-	+
0%	45	0	45	0	45	0	45	0	45	0	45	0
-50%	45	0	45	0	45	0	45	0	45	0	45	0
+50%	1	44	0	45	0	45	2	43	0	45	0	45
+100%	0	45	0	45	0	45	0	45	0	45	0	45

Cross-Reactivity

Cross-reactivity was evaluated by testing saliva controls spiked with structurally similar compounds and/or various drugs and drug metabolites within the same class of drugs.

COMPOUND	CONC. (ng/mL)	% CROSS REACTIVITY
AMPHETAMINE		
d-Amphetamine	50	100%
d,l-Amphetamine	100	50%
R-Amphetamine	2,000	2.5%
d-MDA	150	33.3%
p-Methoxyamphetamine	125	40%
Phentermine	10,000	0%
Tyramine	500	10%
BENZODIAZEPINES		
Oxazepam	10	100%
Alprazolam	10	100%
Bromazepam	200	5%
Chlordiazepoxide	10,000	0%
Clobazam	80	12.5%
Diazepam	20	50%
Flurazepam	10,000	0%
Lorazepam	1,200	0.8%
Lormetazepam	200	5%
Midazolam	10,000	0%
Nitrazepam	8,000	0.1%
Nordiazepam	20	50%
Temazepam	50	20%
Triazolam	10,000	0%
COCAINE		
Cocaine	25	100%
Benzoyllecgonine	50	100%
Ecgonine	2,500	1%
Methyl Ester	12,500	0.2%
METHAMPHETAMINE/ MDMA		
Methamphetamine	50	100%
d,l-Ephedrine	250	20%
1R, 2S, l-Ephedrine	150	33.3%
p-Hydroxymethamphetamine	950	5.3%
MDEA	2,400	2.1%
MDMA	100	50%
d,l-Methamphetamine	150	33.3%
l-Methamphetamine	10,000	0%
Methoxyphenamine	300	16.7%
l-Amphetamine	10,000	0%
OPIATES		
Morphine	40	100%
6-Acetylcodeine	55	72.7%
6-Acetylmorphine	45	88.9%
Codeine	40	100%
Dihydrocodeine	30	133.3%
Ethyl morphine	35	114.3%
Heroin	55	72.7%

Hydrocodone	36	111.1%
Hydromorphone	40	100%
Nalorphine	10,000	0%
Oxycodone	2,300	1.7%
THC		
Δ9-Tetrahydrocannabinol	25	100%
Cannabinol	12.5	200%
Δ-8-Tetrahydrocannabinol	16	160%
11-nor-Δ9-THC-COOH	16	160%
11-Hydroxy-Δ9-THC	12.5	200%

Interference

Interference was evaluated by testing oral fluid controls spiked with endogenous substances, structurally unrelated compounds, and other potential substances that may be present in saliva. The following compounds demonstrated no false positive results on the **ToxWipe™** when tested with concentrations up to 10,000 ng/ml.

Acetaminophen	3-Hydroxybutyric Acid
Acetylsalicylic Acid	Ibuprofen
Amoxicillin	Ketamine
Ampicillin	Loperamide
l-Ascorbic Acid	Naproxen
Bilirubin	Penicillin
Caffeine	Phencyclidine
l-Cotinine	Prednisolone
Diclofenac	Sulfathiazole
Erythromycin	Tetracycline
Estradiol	Thiamine

BIBLIOGRAPHY

- Cone, E. J., and M.A. Huestis. Interpretation of Oral Fluid Tests for Drugs of Abuse. *Annals of the New York Academy of Sciences*. 2007, 1098(1): 51-103.
- Caplan, Y.H. and B.A. Goldberger. Alternative Specimens for Workplace Drug Testing. *Journal of Analytical Toxicology*. 2001, 25(5): 396-399.
- Moore, C. Oral Fluid and Hair in Workplace Drug Testing Programs: New Technology for Immunoassays. *Drug Testing and Analysis*. 2011, 3(3): 166-168.
- O'Neal, C.L., D.J. Crouch, D.E. Rollins, A. Fatah, and M.L. Cheever. Correlation of Saliva Codeine Concentrations with Plasma Concentrations after Oral Codeine Administration. *Journal of Analytical Toxicology*. 1999, 23(6): 452-459.
- Jenkins, A.J., J.M. Oyler, and E.J. Cone. Comparison of Heroin and Cocaine Concentrations in Saliva with Concentrations in Blood and Plasma. *Journal of Analytical Toxicology*. 1995, 19(6): 359-374.



Manufactured by Oranoxis Inc.

9909 Huennekens St. Suite 100, San Diego, Ca 92121 USA



Manufactured for Alere

© 2017 Alere. All rights reserved.

The Alere Logo and Alere are trademarks of the Alere group of companies.

For further information contact your distributor, or call Alere Technical Specialists:

Tel: +61 (07) 3363 7711

Email: au.techsupport@alere.com

Toxwipe PI Rev. 4
Eff. Date 2017-10-04